D8517
Iron–Dextran
95-105 mg/mL (Iron content), solution
Synonym(s):
Ferric hydroxide dextran complex
SMILES string
[Fe].[S](=O)(=O)(O)O
InChI
1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)
InChI key
MVZXTUSAYBWAAM-UHFFFAOYSA-N
biological source
synthetic
sterility
aseptically filled
assay
95-105 mg/mL (Iron content)
form
solution
contains
0.5% phenol as preservative
composition
Iron, ~100 mg/mL
color
brown
useful pH range
4 - 6.5
storage temp.
room temp
Quality Level
Application
Iron-Dextran (ferric hydroxide dextran complex) may be used as an intravenous iron delivery preparation. Iron-Dextran may be used to induce iron-overload to study its effects and preventative measures.
Other Notes
To gain a comprehensive understanding of our extensive range of Dextrans for your research, we encourage you to visit our Carbohydrates Category page.
signalword
Danger
hcodes
Hazard Classifications
Carc. 1B - Skin Sens. 1
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Markus R Jahn et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 78(3), 480-491 (2011-03-29)
The treatment of iron deficiency anemia with polynuclear iron formulations is an established therapy in patients with chronic kidney disease but also in other disease areas like gastroenterology, cardiology, oncology, pre/post operatively and obstetrics' and gynecology. Parenteral iron formulations represent
D L Burns et al.
Nutrition (Burbank, Los Angeles County, Calif.), 11(2), 163-168 (1995-03-01)
Iron dextran was introduced more than 30 yr ago for the parenteral treatment of iron deficiency anemia that is refractory to oral therapy. Iron dextran is a preparation of ferric hydroxide complexed with a low molecular weight fraction of dextran.
Priya Prakash Karmali et al.
Molecular pharmaceutics, 9(3), 539-545 (2012-01-17)
Premature recognition and clearance of nanoparticulate imaging and therapeutic agents by macrophages in the tissues can dramatically reduce both the nanoparticle half-life and delivery to the diseased tissue. Grafting nanoparticles with hydrogels prevents nanoparticulate recognition by liver and spleen macrophages
Maureen M Okam et al.
American journal of hematology, 87(11), E123-E124 (2012-09-12)
Oral iron replacement is the standard therapy in iron-deficiency anemia (IDA). However, 59% of patients have gastrointestinal toxicity. With impaired iron uptake from the gastrointestinal tract (in anemia of chronic disease (ACD) or after bariatric surgery), suboptimal responsiveness to exogenous
C Egger et al.
Ultraschall in der Medizin (Stuttgart, Germany : 1980), 33(6), 587-592 (2012-11-17)
To check the feasibility of the easy quantification of tumor vascularization derived from dynamic contrast-enhanced ultrasound (DCE-US) in comparison to dynamic contrast-enhanced computed tomography (DCE-CT) in patients with hepatocellular carcinoma (HCC). 19 patients with cirrhosis and histologically proven HCC prospectively
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service